Amgen Aktie News

THOUSAND OAKS, Calif. , Oct. 29, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2025 financial results on Tuesday, November 4, 2025, after the close of the U.S. financial markets.

Amgen faced some patent cliffs this year, but its financial results remain strong. It is developing newer medicines that should help it move beyond this challenge.

Slow and steady performers do better over the long term.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Amgen Inc. (NASDAQ: AMGN) breached their fiduciary duties to shareholders. If you currently own Amgen stock and acquired shares on or before July 29, 2020, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-appro...

What's the first thing that springs to mind when someone mentions the Nasdaq Composite?

The U.S. Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic sinus infection, the drugmakers said on Friday.

Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation THOUSAND OAKS, Calif. , Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with na...

Amgen is the latest drugmaker to sell certain drugs directly to consumers amid pressure from President Donald Trump. Meanwhile, Dr. Oz talks GLP-1s for obesity.